Police & Firemen s Retirement System of New Jersey Has $108,000 Stock Position in Stoke Therapeutics, Inc. $STOK

Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 33.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,558 shares of the company’s stock after purchasing an additional 2,384 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Stoke Therapeutics were worth $108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AlphaQuest LLC acquired a new position in Stoke Therapeutics during the 1st quarter worth approximately $72,000. US Bancorp DE increased its holdings in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $92,000. Russell Investments Group Ltd. acquired a new position in shares of Stoke Therapeutics during the first quarter worth approximately $107,000. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Stoke Therapeutics by 131.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock worth $150,000 after purchasing an additional 7,500 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have commented on STOK shares. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Finally, Wedbush boosted their price objective on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and an average price target of $31.00.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $30.89 on Friday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The firm has a 50-day moving average price of $28.29 and a two-hundred day moving average price of $19.17. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 46.10 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 14,922 shares of Stoke Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08. Following the sale, the general counsel directly owned 18,176 shares in the company, valued at $366,064.64. The trade was a 45.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Adrian R. Krainer sold 40,472 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the sale, the director owned 364,246 shares of the company’s stock, valued at $9,827,357.08. This trade represents a 10.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 211,488 shares of company stock worth $5,072,884 over the last 90 days. Company insiders own 9.50% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.